Clinical Trial Update: 68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial evaluating 68Ga-PSMA PET/CT for detecting prostate cancer recurrence in patients with elevated PSA after initial treatment has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Adenocarcinoma
• Prostate Cancer
• Psa Failure

Drugs mentioned

• 68Ga-PSMA PET/CT (68Ga-PSMA PET/CT imaging agent)

Snippet

Sponsor: Andrei Iagaru | Conditions: Prostate Adenocarcinoma, PSA Failure | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2022-01-13